StockWatch
·

Biofrontera Inc. Q2 FY26 Results

BFRIQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue12.0019.1%32.9%
Total Income12.0019.1%32.9%
Expenditure12.5313.0%11.2%
PBT-0.5887.8%89.1%
Net Profit-0.6087.4%88.7%
OPM-4.37%38.47pp51.88pp
NPM-5.03%42.09pp53.93pp
EPS-0.0587.8%91.2%
View full financials

Biofrontera Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

13 Aug 2026 · 13 Aug, 6:38 pm

Summary

Biofrontera Inc. announced strong financial results for the second quarter and first half of 2026, driven by a 32.9% increase in net product revenue to $12.0 million for the quarter and a 25.4% increase to $22.1 million for the first half. The company achieved a significant improvement in gross margin to 80% for both periods, up from 71% and 67% respectively in the prior year, attributed to a lower Ameluz® cost structure. Net loss narrowed considerably, and Adjusted EBITDA showed substantial improvement, moving closer to breakeven. Management expressed optimism about the company's performance, highlighting a restructured cost base, disciplined commercial organization, and accelerating demand for Ameluz®, while also noting progress in the development pipeline with potential new indications.

Key Highlights

  1. 1

    Biofrontera Inc. reported net product revenue of $12.0 million for the second quarter of 2026, an increase of 32.9% compared to $9.0 million in the prior-year period.

  2. 2

    Gross margin improved to 80% in Q2 2026, compared to 71% in the prior-year period, an improvement of approximately 920 basis points.

  3. 3

    The company reported a net loss of $0.6 million, or $(0.05) per share, for Q2 2026, a significant improvement from a net loss of $5.3 million, or $(0.57) per share, in the prior-year period.

  4. 4

    Adjusted EBITDA for Q2 2026 was $(0.2) million, compared to $(5.1) million in the prior-year period, an improvement of approximately $5.0 million.

  5. 5

    For the first half of 2026, net product revenue increased by 25.4% to $22.1 million from $17.6 million in the prior-year period.

  6. 6

    First half 2026 gross margin was 80%, compared to 67% in the prior-year period.

  7. 7

    Cash used in operating activities for the first half of 2026 was reduced by approximately 76% to $1.7 million, compared to $7.2 million in the prior-year period.

Management Comments

H

Hermann Luebbert

This was the strongest operating Q2 and H1 in the Company’s history as a standalone business, and it reflects work that has been underway for more than a year - a restructured cost base, a more disciplined commercial organization, and steady growth in Ameluz® demand. We are seeing the pace of reorders accelerate, which reflects strength of underlying demand. We also continue to be encouraged by the new indications advancing in our development pipeline, including superficial basal cell carcinoma (sBCC), for which we have a PDUFA date in late September of this year and expect to launch in Q1 of 2027. If approved for sBCC, Ameluz will be the first PDT in the United States approved for the treatment of cancerous tumors. Our clinical pipeline also includes recent positive Phase III results in AK on the extremities/neck/trunk and encouraging Phase 2B data in acne that we believe can expand the reach of our PDT platform in the years ahead.

F

Fred Leffler

We see positive effects from the Strategic Transaction and our overall cost management, the impacts of which are now visible in the Q2 results. Gross margin improved roughly 920 basis points year over year, operating expenses declined 11%, and we brought Adjusted EBITDA to within $0.2 million of breakeven. Operating cash used in the first half of 2026 was $1.7 million, down from $7.2 million a year ago. That figure includes a $3.7 million paydown of related party payables connected to the Strategic Transaction. Excluding that item, changes in working capital would have been a net source of cash in the first half. We continue to make progress towards cash flow breakeven in 2026.

Informational and educational content only. Not investment advice.